EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

EV68-228-N monoclonal antibody treatment halts progression of paralysis in a mouse model of EV-D68 induced acute flaccid myelitis

Michael J Rudy iD, Courtney J Wilson, Brendan Hinckley, Danielle C Baker, Joshua M Royal, Marshall P Hoke, Miles B Brennan, Matthew R Vogt, Penny Clarke iD, Kenneth L Tyler iD

mBio · 09.04.2025 · 16 (4)

DOI: 10.1128/mbio.03906-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift mBio, erschienen am 09.04.2025. Verfasst von Michael J Rudy und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, University of Colorado, Aurora, Colorado, USA. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Antibodies, Viral, Central Nervous System Viral Diseases, Enterovirus D, Human. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID), KBio, Owensboro, KY.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

In 2014, 2016, and 2018, infection with enterovirus D68 (EV-D68) was associated with outbreaks of a poliomyelitis-like paralytic syndrome, called acute flaccid myelitis (AFM). While only a small fraction of patients infected with EV-D68 developed AFM, this subgroup of patients does not typically seek treatment until after the onset of neurological symptoms. There are currently no approved human monoclonal antibody therapies or vaccines available for EV-D68. Here, we show that a monoclonal antibody, EV68-228-N, can quickly stop the progression of paralysis in a mouse model of AFM, even when treatment is initiated after the onset of paralysis. We found that EV68-228-N effectively halted the progression of paralysis when tested against both 2014 and 2016 EV-D68 isolates in an immunocompetent mouse model of AFM. All animal experiments were conducted in a blinded fashion. The IC 50 of EV68-228-N against 2014 and 2016 EV-D68 isolates was confirmed in vitro to be less than 330 ng/mL, and EV68-228-N was found to be equally effective at neutralizing 2018 and 2022 viral isolates without any evidence of emerging resistance. We further show that, following infection with EV-D68, mice treated with EV68-228-N have more surviving motor neurons in the spinal cord’s lumbar enlargement than control treated animals. Taken together, this work suggests that EV68-228-N treatment has the potential to halt the progression of paralysis in AFM patients who present at the clinic with neurologic symptoms and that EV68-228-N will retain neutralization potential against emerging EV-D68 isolates. IMPORTANCE Enterovirus D-68 (EV-D68) associated acute flaccid myelitis (AFM) is an emergent poliomyelitis-like illness occurring predominantly in children. There are currently no proven effective therapies. We describe the use of a human monoclonal antibody (EV68-228-N) in a murine model of EV-D68 AFM in which therapy prevents progression of paralysis even when treatment is instituted after onset of weakness. Clinical Trials This study is registered with ClinicalTrials.gov as NCT06444048 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, MonoclonalAntibodies, ViralCentral Nervous System Viral DiseasesEnterovirus D, HumanEnterovirus InfectionsMyelitisNeuromuscular DiseasesParalysisAnimalsFemaleHumansMiceAntibodies, NeutralizingDisease Models, AnimalDisease Progression

Stichwörter der Autor:innen

Enterovirus D-68acute flaccid myelitismonoclonal antibodiestreatment

Substanzen

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, Viral

Autor:innen und Institutionen

  • Department of Neurology, University of Colorado, Aurora, Colorado, USA.
  • Department of Research and Discovery, KBio Inc., Owensboro, Kentucky, USA.
  • Department of Regulatory Affairs, ZabBio Inc., San Diego, California, USA.
  • Borrasca Consulting LLC, Denver, Colorado, USA.
  • Departments of Pediatrics and Microbiology and Immunology, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, North Carolina, USA.
  • Department of Immunology and Microbiology, University of Colorado, Aurora, Colorado, USA.

ORCID-Profile: Michael J Rudy, Penny Clarke, Kenneth L Tyler

Förderung

  • NIAID NIH HHS
  • HHS | NIH | National Institute of Allergy and Infectious Diseases (NIAID)
  • KBio, Owensboro, KY

Zitieren

APA

Rudy, M. J., Wilson, C. J., Hinckley, B., Baker, D. C., Royal, J. M., Hoke, M. P., Brennan, M. B., Vogt, M. R., Clarke, P., & Tyler, K. L. (2025). EV68-228-N monoclonal antibody treatment halts progression of paralysis in a mouse model of EV-D68 induced acute flaccid myelitis. mBio, 16(4). https://doi.org/10.1128/mbio.03906-24

Vancouver

Rudy MJ, Wilson CJ, Hinckley B, Baker DC, Royal JM, Hoke MP, et al. EV68-228-N monoclonal antibody treatment halts progression of paralysis in a mouse model of EV-D68 induced acute flaccid myelitis. mBio. 2025;16(4). doi:10.1128/mbio.03906-24

BibTeX
@article{Rudy2025,
  author = {Rudy, Michael J and Wilson, Courtney J and Hinckley, Brendan and Baker, Danielle C and Royal, Joshua M and Hoke, Marshall P and Brennan, Miles B and Vogt, Matthew R and Clarke, Penny and Tyler, Kenneth L},
  title = {EV68-228-N monoclonal antibody treatment halts progression of paralysis in a mouse model of EV-D68 induced acute flaccid myelitis},
  journal = {mBio},
  year = {2025},
  volume = {16},
  number = {4},
  doi = {10.1128/mbio.03906-24}
}
Kostenlos starten →